This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi (SNY) Gets CHMP Nod for Enjaymo in Hemolytic Anemia
by Zacks Equity Research
The CHMP recommends authorizing Sanofi's (SNY) Enjaymo as a treatment for hemolytic anemia in patients with cold agglutinin disease (CAD). The CHMP endorses SNY's RSV vaccine for use in infants.
AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID
by Zacks Equity Research
CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
by Zacks Equity Research
AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.
Pharma Stock Roundup: J&J New Buyback Plan, CHMP Nod to PFE's BA.4, BA.5 Omicron Jab
by Kinjel Shah
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
Key Factors Driving Merck's (MRK) Outperformance This Year
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Is JPMorgan Diversified Return International Equity ETF (JPIN) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPIN
Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates
by Kinjel Shah
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.
AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancer
AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment
by Zacks Equity Research
AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.
Moderna's (MRNA) Omicron Based Jab gets Approval in Australia
by Zacks Equity Research
Moderna (MRNA) receives provisional approval in Australia for its Omicron-containing bivalent booster vaccine mRNA-1273.214 in adults, making it the first bivalent COVID-19 vaccine approved for use in Australia.
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
by Zacks Equity Research
Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
by Zacks Equity Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs
by Zacks Equity Research
The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.
Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study
by Zacks Equity Research
Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Merck (MRK) Enters Into Circular RNA Collaboration With Orna
by Zacks Equity Research
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
by Zacks Equity Research
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
by Kinjel Shah
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down
by Zacks Equity Research
Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.